Broad-spectrum antiviral therapies do not exist, tragically hindering our ability to respond to viral outbreaks and pandemics. We need new approaches to treat these diseases, as existing therapeutics are very narrow-spectrum and take many years to develop. Carver Biosciences is a startup company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The underlying technology, CARVER, was developed by founder Cameron Myhrvold during his time as a postdoc at the Broad Institute of MIT and Harvard and was published in Molecular Cell in 2019. Carver recently closed a seed round and is looking to expand it's team.
Lithium-ion (Li-ion) batteries are used in many products such as electronics, toys, wireless headphones, handheld power tools, small and large appliances, electric vehicles, and electrical energy storage systems. If not properly managed at the end of their useful life, they can cause harm to human health or the environment. Princeton NuEnergy is revolutionizing the material supply chain with its patented low-cost process for producing high quality cathode active materials from spent lithium ion batteries. With successful operation of our lab scale plant and strong relationships throughout the electric vehicle supply chain we are building out our team to execute our production scale manufacturing plants starting in 2021.
Viral infections causing hepatitis are major contributors to human morbidity and mortality. Currently, there are no approved directly acting antivirals that cure two of these viruses - hepatitis B (HBV) and E viruses (HEV) – that account for close to 300 million infections world-wide. Our goal is to develop novel small molecule therapeutics that can be readily deployed to combat efficiently these diseases. To achieve this, we capitalize on discoveries and technical advances from our lab that put us in a unique position for targeted high through-put screens. We have already identified a lead molecule that is effective against multiple HEV genotypes, and we have uncovered a minimal set of host factors that are essential for HBV persistence.
Antimicrobial resistance is emerging as a growing global threat. Currently, more than 10 million people per year become infected by drug-resistant bacteria and those numbers are predicted to grow exponentially in the coming years. There is thus a pressing need for new antibiotics, and in particular for antibiotics with novel mechanisms of action. To address this need we have developed a novel pipeline for rapidly determining the mechanism of action of candidate antibiotics. With this approach we can fundamentally change the traditional antibiotic discovery pipeline by focusing our efforts on compounds with novel mechanisms of action (instead of the traditional efforts that prioritize based on chemical features and efficacy, leading to the rediscovery of similar compounds time and time again).
Many skin care products are damaging to the environment and potentially the consumer as well. Non-biodegradable cosmetics, especially those with plastic particles, can end up damaging aquatic life. The rising trend of environmental consciousness in consumers and regulations emphasizes the need for responsible products. Prisili products use natural materials and flash nanoprecipitation to encapsulate all natural and environmentally friendly skin care products.
Andluca Technologies designs transparent, thin-film power sources that convert ultraviolet light into useful energy at the point of use. These flexible power sources can conform to any shape and disappear into their environment to enable discreet, wireless operation of smart glass. Beyond buildings, our technologies are unlocking new functionalities in the automobile, aviation, military, eyewear, health and IoT sectors. Andluca Technologies was established in 2017 following over 12 years of research on light-responsive films by Professor Lynn Loo and her team at the Organic and Polymer Electronics Laboratory at Princeton University.
Kayothera is leveraging cutting-edge discoveries to develop therapeutics for cancer patients who currently receive terminal diagnoses. Our two pipeline candidates target solid tumors to 1) inhibit tumor survival mechanisms in advanced or chemoresistant disease, 2) deplete immunosuppressive Regulatory T cells to restore anti-tumor immunity. With these first-in-class small molecule therapeutics, we aim to give hope to patients with intractable cancers.
Tendo Technologies, founded in 2017, is a spin-off from the Marcus Hultmark research lab at Princeton developing a novel flow sensing/measurement technology. This unique technology achieves extreme sensitivity (for both gases and liquids) through the nanoscale conductive ribbons that will deflect when placed in flow. The nanoribbons are manufactured with standard semiconductor-based techniques, resulting in high scalability and low unit cost for the sensing chip. As a highly versatile technology (flow measurement is ubiquitous), Tendo envisions that their tech can be applied in many industries for various applications, when equipped with appropriate "wrappers" around it. For example, the Tendo chip plus communication package would be appropriate for IoT applications such as real time air measurement in HVAC ducts; alternatively, more sophisticated housing with control would bring benefits for flow metering and control during industry manufacturing processes.